Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038326 | 0.86 | POLB (0.55) | POLBHTTCTSSLMNAHSD17B10 | |
| SCHEMBL6038072 | 0.82 | POLB (0.60) | POLBHTTCTSSLMNAHSD17B10 | |
| SCHEMBL6038332 | 0.80 | POLB (0.50) | POLBHTTCTSSLMNAHSD17B10 | |
| SCHEMBL6037997 | 0.78 | LMNA (0.38) | POLBLMNAGAAALDH1A1TP53 | |
| SCHEMBL6038008 | 0.78 | HDAC3 (0.51) | POLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6038010 | 0.78 | HDAC3 (0.51) | POLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6038028 | 0.75 | LMNA (0.48) | LMNAHSD17B10GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5284999 | 0.71 | CTSS (0.49) | POLBHTTCTSSLMNAHSD17B10 | |
| SCHEMBL6037915 | 0.71 | LMNA (0.50) | LMNAGAAALDH1A1 | |
| SCHEMBL5284939 | 0.71 | KMT2A (0.42) | POLBHTTCTSSLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | POLB 820/4885HTT 846/4885CTSS 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.